LGVN News and Press, Longeveron Inc.

Longeveron (NASDAQ: LGVN) , a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, will be represented at next month’s 2024 BIO International Convention; the convention is scheduled to take plac...

MIAMI, May 28, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that the Company will participate in the BIO Internat...

2024-05-17 23:08:05 ET Longeveron Inc. (LGVN) Q1 2024 Earnings Conference Call May 14, 2024, 05:00 PM ET Company Participants Derek Cole - IR, Advisory Solutions Wa'el Hashad - CEO Nataliya Agafonova - Chief Medical Officer Lisa Locklear - CFO Joshua Hare...

2024-05-15 08:31:48 ET More on Longeveron Longeveron announces board transitions Longeveron stock rallies 85% on Alzheimer's presentation (update) Seeking Alpha’s Quant Rating on Longeveron Historical earnings data for Longeveron Read the ful...

Phase 2b clinical trial evaluating Lomecel-B TM in rare pediatric disease HLHS on track for completing enrollment by end of 2024 Data from Phase 2a clinical trial evaluating Lomecel-B TM in Alzheimer’s Disease selected for Featured Research Oral Presentation at 2024 Alzheimer...

Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, is reporting changes on its board of directors. The following transitions on the board have been announced: Richard Kender, retired SVP of bu...

2024-05-10 16:15:05 ET More on Longeveron Longeveron Inc. (LGVN) Q4 2023 Earnings Call Transcript Longeveron stock rallies 85% on Alzheimer's presentation (update) Longeveron stock rallies 75% amid public offering, business update Seeking Alpha’s Quant...

Richard Kender, retired SVP of Business Development and Corporate Licensing for Merck & Co., Inc., has been appointed to the Longeveron Board Dr. Roger Hajjar, former head of R&D at Ring Therapeutics, has been nominated as a candidate for the Board, subject to election at the Compan...

Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, will be releasing its fi...

MIAMI, May 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will report first quarter 2024 financial results and provide a business update on Tuesday, May 14, 2024 after the U.S. fina...